Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Gujarat Kidney And Super Speciality Debt-to-EBITDA?
Gujarat Kidney And Super SpecialityNSE:GKSL +1.39%18 Debt-to-EBITDA is 1.04 as of Mar. 2026, which is 18% below its 10-year median of 1.27. GuruFocus rates NSE:GKSL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Gujarat Kidney And Super Speciality ranks better than 69.04% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
NSE:GKSL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.05 Med: 1.27 Max: 1.36
Current: 1.05
During the past 4 years, the highest Debt-to-EBITDA Ratio of Gujarat Kidney And Super Speciality was 1.36. The lowest was 1.05. And the median was 1.27.
NSE:GKSL's Debt-to-EBITDA is ranked better than 69.04% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs NSE:GKSL: 1.05
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Gujarat Kidney And Super Speciality Debt-to-EBITDA Related Terms
Gujarat Kidney And Super Speciality Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality Debt-to-EBITDA Chart
Gujarat Kidney And Super Speciality Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Debt-to-EBITDA
1.29
1.24
1.36
1.05
Gujarat Kidney And Super Speciality Quarterly Data
NSE:GKSL vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Gujarat Kidney And Super Speciality's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Kidney And Super Speciality Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Gujarat Kidney And Super Speciality's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gujarat Kidney And Super Speciality's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Gujarat Kidney And Super Speciality (NSE:GKSL) has a Debt-to-EBITDA of 1.04 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gujarat Kidney And Super Speciality. This is 18% below median its historical median of 1.27. Over the past decade, Gujarat Kidney And Super Speciality's Debt-to-EBITDA has ranged from 1.05 to 1.36. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #148 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 31%.
Is Gujarat Kidney And Super Speciality's Debt-to-EBITDA too high?
Gujarat Kidney And Super Speciality's current Debt-to-EBITDA of 1.04 is 18% below median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 1.36. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Gujarat Kidney And Super Speciality's value of 1.04 is 52.6% below this industry median. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #148 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #148 out of 478 companies for Debt-to-EBITDA. This puts Gujarat Kidney And Super Speciality in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. Gujarat Kidney And Super Speciality's value of 1.04 is 52.6% below this benchmark. Historically, Gujarat Kidney And Super Speciality's own Debt-to-EBITDA has ranged from 1.05 to 1.36 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 2.20, Gujarat Kidney And Super Speciality has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Kidney And Super Speciality's current Debt-to-EBITDA of 1.04 is 52.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gujarat Kidney And Super Speciality. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current Debt-to-EBITDA is 1.04, which is 18% below median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current Debt-to-EBITDA of 1.04. The current Debt-to-EBITDA is 1.04, which is 18% below median its 10-year median of 1.27 and 52.6% below the Healthcare Providers & Services industry median of 2.20. Gujarat Kidney And Super Speciality's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current Debt-to-EBITDA is 1.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
18GF Score
Get the complete analysis for NSE:GKSL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKSL has been successfully added to your 
